Everything You Should Know About the Upgrade of Rezolute (RZLT) Rating to Buy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy RZLT?
Source: NASDAQ.COM
Rezolute's Upgrade: Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy) due to a positive shift in earnings estimates, indicating a favorable outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with stock price movements, making Rezolute a solid candidate for potential market-beating returns.
Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Rezolute has increased by 17.4%, reflecting analysts' growing confidence in the company's earnings potential.
Investment Strategy: The Zacks Rank system maintains a balanced approach to stock ratings, ensuring that only the top 20% of stocks based on earnings revisions receive a "Buy" or "Strong Buy" rating, positioning Rezolute favorably for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 2.990
Low
2.00
Averages
6.29
High
20.00
Current: 2.990
Low
2.00
Averages
6.29
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rezolute Shares Rise After Positive FDA Meeting Outcome
- Positive FDA Meeting Outcome: Rezolute's shares rose after a meeting with the U.S. FDA, which acknowledged the potential impact of behavioral factors on patients in studies, indicating possible support for ersodetug despite last year's primary endpoint failure.
- Clinical Trial Challenges: The FDA recognized the limitations of relying on self-monitored blood glucose metrics to measure hypoglycemia in the sunRIZE study, suggesting that Rezolute may need to optimize its research design moving forward.
- Market Application Prospects: The FDA encouraged Rezolute to submit study data for independent review, with a decision expected on whether the sunRIZE data will suffice for a marketing application or if additional data will be required, directly impacting the company's market strategy.
- CEO's Positive Remarks: CEO Nevan Charles Elam expressed strong encouragement from the meeting's outcome, emphasizing that the FDA did not outright dismiss sunRIZE for not meeting its primary endpoint, indicating hope for the company's future clinical development.
See More
Faruqi & Faruqi Investigates Rezolute Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. after its stock plummeted on December 11, 2025, due to disappointing results from a clinical trial, indicating significant legal risks for the company.
- Clinical Trial Failure: The Phase 3 sunRIZE clinical trial for Rezolute's lead drug candidate failed to meet both primary and key secondary endpoints, leading to a loss of investor confidence and a sharp decline in stock price, highlighting major challenges in the company's drug development efforts.
- Significant Investor Losses: Following the poor clinical trial results, shareholders of Rezolute may face substantial financial losses, prompting Faruq & Faruqi to encourage affected investors to reach out directly to discuss their legal rights and options for claims.
- Law Firm Background: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which may provide strong support for affected investors.
See More
Faruqi & Faruqi Investigates Losses in Rezolute Stock
- Stock Price Plunge: Rezolute, Inc. shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, reflecting an 85-90% drop and investor disillusionment with the company's prospects.
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, urging investors who suffered significant losses to contact partner Josh Wilson directly, indicating the firm's commitment to protecting investor rights.
- Clinical Trial Failure: The lead drug candidate ersodetug failed to meet both primary and key secondary endpoints in clinical trials, leading to a significant decline in market confidence and the potential for increased legal actions against the company.
- Investor Rights Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its expertise in securities law and aiming to provide legal support for affected investors.
See More
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options
- Legal Consultation Advocacy: Faruq & Faruqi's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Rezolute stock or options to contact him directly, highlighting the firm's commitment to investor rights.
- Potential Claims Investigation: The firm is investigating potential claims against Rezolute, Inc., indicating that the company may face legal risks, which investors should monitor to protect their interests.
- Investor Loss Focus: Faruq & Faruqi emphasizes that investors who have incurred significant losses in Rezolute should seek legal advice promptly, reflecting a proactive approach to investor protection and potential compensation.
- Firm Background Overview: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, thereby enhancing investor trust in its services.
See More
Rezolute, Inc. Faces Investigation After 87.2% Stock Drop Following Phase 3 Study Results
- Stock Price Plunge: Rezolute, Inc. experienced a staggering 87.2% drop in stock price, falling from $9.44 to $1.77 following the release of its Phase 3 sunRIZE study results, indicating extreme pessimism among investors regarding the company's future prospects.
- Disappointing Study Results: The study failed to meet its primary endpoint, with only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to the placebo group's 40% improvement, highlighting the limited efficacy of the drug.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Rezolute engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further undermine shareholder confidence.
- Strong Market Reaction: The significant stock decline following the failure to meet key secondary endpoints reflects a severe lack of confidence in Rezolute's research capabilities and the future marketability of its products.
See More
Rezolute Shares Plunge 85% Following Failed Clinical Trial, Legal Investigation Initiated
- Stock Plunge: Rezolute, Inc. shares plummeted approximately 85%-90% on December 11, 2025, dropping from around $10.94 to an intraday low of $0.90 due to disappointing results from its Phase 3 sunRIZE clinical trial, indicating severe investor disillusionment with the company's prospects.
- Clinical Trial Failure: The trial failed to meet both primary and key secondary endpoints, with the highest dose showing no statistically significant reductions in hypoglycemia events compared to placebo, directly impacting investor confidence and market performance.
- Legal Investigation Initiated: Faruqi & Faruqi LLP is investigating potential claims against Rezolute, encouraging investors who suffered significant losses to reach out, highlighting the market's concern over the company's future legal risks and potential liabilities.
- Severe Market Reaction: The stock's dramatic decline led to a trading halt by Nasdaq under volatility controls, reflecting a complete erosion of market confidence in Rezolute, which may prompt more investors to seek legal recourse.
See More
Rezolute Shares Rise After Positive FDA Meeting Outcome
- Positive FDA Meeting Outcome: Rezolute's shares rose after a meeting with the U.S. FDA, which acknowledged the potential impact of behavioral factors on patients in studies, indicating possible support for ersodetug despite last year's primary endpoint failure.
- Clinical Trial Challenges: The FDA recognized the limitations of relying on self-monitored blood glucose metrics to measure hypoglycemia in the sunRIZE study, suggesting that Rezolute may need to optimize its research design moving forward.
- Market Application Prospects: The FDA encouraged Rezolute to submit study data for independent review, with a decision expected on whether the sunRIZE data will suffice for a marketing application or if additional data will be required, directly impacting the company's market strategy.
- CEO's Positive Remarks: CEO Nevan Charles Elam expressed strong encouragement from the meeting's outcome, emphasizing that the FDA did not outright dismiss sunRIZE for not meeting its primary endpoint, indicating hope for the company's future clinical development.
See More
Faruqi & Faruqi Investigates Rezolute Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, Inc. after its stock plummeted on December 11, 2025, due to disappointing results from a clinical trial, indicating significant legal risks for the company.
- Clinical Trial Failure: The Phase 3 sunRIZE clinical trial for Rezolute's lead drug candidate failed to meet both primary and key secondary endpoints, leading to a loss of investor confidence and a sharp decline in stock price, highlighting major challenges in the company's drug development efforts.
- Significant Investor Losses: Following the poor clinical trial results, shareholders of Rezolute may face substantial financial losses, prompting Faruq & Faruqi to encourage affected investors to reach out directly to discuss their legal rights and options for claims.
- Law Firm Background: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which may provide strong support for affected investors.
See More
Faruqi & Faruqi Investigates Losses in Rezolute Stock
- Stock Price Plunge: Rezolute, Inc. shares plummeted on December 11, 2025, due to disappointing results from its Phase 3 sunRIZE clinical trial, collapsing from approximately $10.94 to $0.90, reflecting an 85-90% drop and investor disillusionment with the company's prospects.
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Rezolute, urging investors who suffered significant losses to contact partner Josh Wilson directly, indicating the firm's commitment to protecting investor rights.
- Clinical Trial Failure: The lead drug candidate ersodetug failed to meet both primary and key secondary endpoints in clinical trials, leading to a significant decline in market confidence and the potential for increased legal actions against the company.
- Investor Rights Protection: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its expertise in securities law and aiming to provide legal support for affected investors.
See More
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options
- Legal Consultation Advocacy: Faruq & Faruqi's Securities Litigation Partner Josh Wilson encourages investors who have suffered significant losses in Rezolute stock or options to contact him directly, highlighting the firm's commitment to investor rights.
- Potential Claims Investigation: The firm is investigating potential claims against Rezolute, Inc., indicating that the company may face legal risks, which investors should monitor to protect their interests.
- Investor Loss Focus: Faruq & Faruqi emphasizes that investors who have incurred significant losses in Rezolute should seek legal advice promptly, reflecting a proactive approach to investor protection and potential compensation.
- Firm Background Overview: Since its founding in 1995, Faruq & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, thereby enhancing investor trust in its services.
See More
Rezolute, Inc. Faces Investigation After 87.2% Stock Drop Following Phase 3 Study Results
- Stock Price Plunge: Rezolute, Inc. experienced a staggering 87.2% drop in stock price, falling from $9.44 to $1.77 following the release of its Phase 3 sunRIZE study results, indicating extreme pessimism among investors regarding the company's future prospects.
- Disappointing Study Results: The study failed to meet its primary endpoint, with only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to the placebo group's 40% improvement, highlighting the limited efficacy of the drug.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Rezolute engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further undermine shareholder confidence.
- Strong Market Reaction: The significant stock decline following the failure to meet key secondary endpoints reflects a severe lack of confidence in Rezolute's research capabilities and the future marketability of its products.
See More
Rezolute Shares Plunge 85% Following Failed Clinical Trial, Legal Investigation Initiated
- Stock Plunge: Rezolute, Inc. shares plummeted approximately 85%-90% on December 11, 2025, dropping from around $10.94 to an intraday low of $0.90 due to disappointing results from its Phase 3 sunRIZE clinical trial, indicating severe investor disillusionment with the company's prospects.
- Clinical Trial Failure: The trial failed to meet both primary and key secondary endpoints, with the highest dose showing no statistically significant reductions in hypoglycemia events compared to placebo, directly impacting investor confidence and market performance.
- Legal Investigation Initiated: Faruqi & Faruqi LLP is investigating potential claims against Rezolute, encouraging investors who suffered significant losses to reach out, highlighting the market's concern over the company's future legal risks and potential liabilities.
- Severe Market Reaction: The stock's dramatic decline led to a trading halt by Nasdaq under volatility controls, reflecting a complete erosion of market confidence in Rezolute, which may prompt more investors to seek legal recourse.
See More
